Pathogen/microbe-associated molecular patterns(PAMPs/MAMPs) are recognized by plant pattern recognition receptors(PRRs)localized on the cell surface to activate immune responses.This PAMP-triggered immunity(PTI) confe...Pathogen/microbe-associated molecular patterns(PAMPs/MAMPs) are recognized by plant pattern recognition receptors(PRRs)localized on the cell surface to activate immune responses.This PAMP-triggered immunity(PTI) confers resistance to a broad range of pathogenic microbes and,therefore,has a great potential for genetically engineering broad-spectrum resistance by transferring PRRs across plant families.Pathogenic effectors secreted by phytopathogens often directly target and inhibit key components of PTI signaling pathways via diverse biochemical mechanisms.In some cases,plants have evolved to produce decoy proteins that mimic the direct virulence target,which senses the biochemical activities of pathogenic effectors.This kind of perception traps the effectors of erroneous targeting and results in the activation of effector-triggered immunity(ETI) instead of suppressing PTI.This mechanism suggests that artificially designed decoy proteins could be used to generate new recognition specificities in a particular plant.In this review,we summarize recent advances in research investigating PAMP recognition by PRRs and virulence effector surveillance by decoy proteins.Successful expansion of recognition specificities,conferred by the transgenic expression of EF-Tu receptor(EFR) and AvrPphB susceptible 1(PBS1) decoys,has highlighted the considerable potential of PRRs and artificially designed decoys to expand plant resistance spectra and the need to further identify novel PRRs and decoys.展开更多
T cells, genetically modified by chimeric antigen receptors(CAR-T), are endowed with specificity to a desired antigen and are cytotoxic to cells expressing the targeted antigen. CAR-T-based cancer immunotherapy is a p...T cells, genetically modified by chimeric antigen receptors(CAR-T), are endowed with specificity to a desired antigen and are cytotoxic to cells expressing the targeted antigen. CAR-T-based cancer immunotherapy is a promising therapy for curing hematological malignancy, such as acute lymphoid leukemia, and is promising for extending their efficacy to defeat solid tumors. To date, dozens of different CAR-T cells have been evaluated in clinical trials to treat tumors; this necessitates the establishment of guidelines for the production and application of CAR-T cells. However, it is challenging to standardize CAR-T cancer therapy because it involves a combination of gene therapy and cell therapy. In this review, we compare the existing guidelines for CAR-T cells and discuss the challenges and considerations for establishing guidance for CAR-T-based cancer immunotherapy.展开更多
基金supported by the Strategic Priority Research Program of the Chinese Academy of Sciences(XDB11020600)National Natural Science Foundation of China(31571968,31300234)the Youth Innovation Promotion Association of the Chinese Academy of Sciences
文摘Pathogen/microbe-associated molecular patterns(PAMPs/MAMPs) are recognized by plant pattern recognition receptors(PRRs)localized on the cell surface to activate immune responses.This PAMP-triggered immunity(PTI) confers resistance to a broad range of pathogenic microbes and,therefore,has a great potential for genetically engineering broad-spectrum resistance by transferring PRRs across plant families.Pathogenic effectors secreted by phytopathogens often directly target and inhibit key components of PTI signaling pathways via diverse biochemical mechanisms.In some cases,plants have evolved to produce decoy proteins that mimic the direct virulence target,which senses the biochemical activities of pathogenic effectors.This kind of perception traps the effectors of erroneous targeting and results in the activation of effector-triggered immunity(ETI) instead of suppressing PTI.This mechanism suggests that artificially designed decoy proteins could be used to generate new recognition specificities in a particular plant.In this review,we summarize recent advances in research investigating PAMP recognition by PRRs and virulence effector surveillance by decoy proteins.Successful expansion of recognition specificities,conferred by the transgenic expression of EF-Tu receptor(EFR) and AvrPphB susceptible 1(PBS1) decoys,has highlighted the considerable potential of PRRs and artificially designed decoys to expand plant resistance spectra and the need to further identify novel PRRs and decoys.
基金supported by the National High Technology Research and Development Program of China (2014AA020704)the National Natural and Scientific Foundation of China (81201789/H1611, 81572981/H1611, 81400057/H0111)
文摘T cells, genetically modified by chimeric antigen receptors(CAR-T), are endowed with specificity to a desired antigen and are cytotoxic to cells expressing the targeted antigen. CAR-T-based cancer immunotherapy is a promising therapy for curing hematological malignancy, such as acute lymphoid leukemia, and is promising for extending their efficacy to defeat solid tumors. To date, dozens of different CAR-T cells have been evaluated in clinical trials to treat tumors; this necessitates the establishment of guidelines for the production and application of CAR-T cells. However, it is challenging to standardize CAR-T cancer therapy because it involves a combination of gene therapy and cell therapy. In this review, we compare the existing guidelines for CAR-T cells and discuss the challenges and considerations for establishing guidance for CAR-T-based cancer immunotherapy.
